Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. As of December 12, 2025, the company has repurchased a total of 2,632,446 ordinary fully paid securities, with 111,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services. The company is known for its diagnostic testing services, catering to a wide range of medical needs across Australia.
Average Trading Volume: 798,604
Technical Sentiment Signal: Buy
Current Market Cap: A$550.6M
Learn more about ACL stock on TipRanks’ Stock Analysis page.